Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Account Payables (2019 - 2025)

Historic Change in Account Payables for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to -$3.0 million.

  • Keros Therapeutics' Change in Account Payables fell 8561.56% to -$3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.6 million, marking a year-over-year decrease of 33869.49%. This contributed to the annual value of -$249000.0 for FY2024, which is 11542.75% down from last year.
  • Keros Therapeutics' Change in Account Payables amounted to -$3.0 million in Q3 2025, which was down 8561.56% from -$1.4 million recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Change in Account Payables registered a high of $4.7 million during Q2 2022, and its lowest value of -$5.0 million during Q3 2022.
  • For the 5-year period, Keros Therapeutics' Change in Account Payables averaged around $7263.2, with its median value being $23000.0 (2024).
  • As far as peak fluctuations go, Keros Therapeutics' Change in Account Payables plummeted by 77472.53% in 2024, and later surged by 867826.09% in 2025.
  • Keros Therapeutics' Change in Account Payables (Quarter) stood at $823000.0 in 2021, then decreased by 27.7% to $595000.0 in 2022, then surged by 75.46% to $1.0 million in 2023, then crashed by 128.07% to -$293000.0 in 2024, then tumbled by 908.53% to -$3.0 million in 2025.
  • Its last three reported values are -$3.0 million in Q3 2025, -$1.4 million for Q2 2025, and $2.0 million during Q1 2025.